PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known	
Application Number	10/647,358
Filing Date	August 25, 2003
First Named Inventor	Charles Larry Bisgaier
Art Unit	1617
Examiner Name	Edward J. Webman
Attorney Docket Number	5790-C1

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		"H. Fiesler, et al., Clin. Chim. Acta ,Serum Lp(a) concentrations are unaffected by treatment with HMG-CoA reductase inhibitor pravastatin: result of a 2-year investigation", 204, 291-300 (1991)	
		C. Wanner et al., Clin. Nephrol"Effects of simvastatin on lipoprotein(a)and lipoprotein composition in patients with nephrotic syndrome", 41, 138-143 (1994).	
		F. Umeda et al., Endocrin, Japan"Effect of pravastatin on serum lipids, apolipoprotein and lipoprotei(a) in patients with non-insulin dependent diabetes mellitus", 39, 45-50 (1992).	
		D. Hunninghake et. al., J. Clin. Pharmacol.,"Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein-a", 33, 574-580 (1994).	
		The Simvastatin Pravastatin Study Group, Am. J. Cardiol.,"Group TSPS. Comparison of the efficacy, safety, and tolerability of simvastatin and pravastatin fir hypercholesterolemia", 71, 1408-1414 (1993)	
		E. Leitersdorf et. al., Circulation,"Genetic determinants of responsiveness to the HMG-CoA reducatase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia", 87, 35-44 (1993).	
		J. McKenny et. al., Am. J. Med.,"A randomized trial of the effects of atorvastatin and niacin in patients with combined lipidemia or hypertriglyceridemia", 104, 137-143 (1998)	
		T. Sampietro et. al., Cardiovasc. Drug Therapy,"Behavior of Lp(a) and apolipoproteins (A1, B, C2, C3, E) during and after therpy with simvastatin", 9, 785-789 (1995).	
		I. Klausen et. al., Eur. J. Clin.. Invest.,"Apolipoprotei(a) polymorphism predicts theincrease of Lp(a) by prevastatin in patients with familial hypercholesterolemia treated with bile acid sequestration", 23, 240-245 (1993)	
		S. Gonbert et. al., Atherosclerosis, "Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levelsin hypercholesterolemic subjects at high cardiovascular risk", 164, 305-311 (2002).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/647358
Filing Date	August 25, 2003
First Named Inventor	Charles Larry Bisgaier
Art Unit	1617
Examiner Name	Edward J. Webman
Attorney Docket Number	5790-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		E. Schaefer et. al., Am. J. Cardiol.,Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects", 93, 31-39 (2004).	
		H. Hobbs, et. al., Curr. Op. Lip. Lipoprotein(a): intrigues and insights", 10(3) 225-236 (June 1999).	
		S. Van Wissen, Heart"Long term statin treatment reduces lipoprotein (a) concentrations in heterozygous familial hypercholesterolemia", 89, 893-896 (2003).	
		"	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.